Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PHEBURANE® (sodium phenylbutyrate) is indicated adjunctive therapy to standard of care, which includes dietary management, for chronic management of adult and pediatric patients with UCDs.
Product Name : Pheburane
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2022
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dequalinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vablys® (dequalinium chloride vaginal tablets), is the first prescription antiseptic and anti-infective treatment for bacterial vaginosis in women under 55 years of age.
Product Name : Vablys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2022
Lead Product(s) : Dequalinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Population Council
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Population Council and Duchesnay Announce New International License Agreement for ANNOVERA®
Details : As part of the agreement, Duchesnay will explore opportunities to register ANNOVERA with local regulatory agencies in these regions and will invest in the Population Council’s research activities to develop new innovative contraceptive products.
Product Name : Annovera
Product Type : Steroid
Upfront Cash : Undisclosed
November 30, 2020
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Population Council
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ospemifene
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Plushcare
Deal Size : Undisclosed
Deal Type : Partnership
Details : The aim of this partnership is to provide Duchesnay USA's Osphena® (ospemifene) to women suffering from vaginal symptoms related to menopause, with the possibility of having this conversation with a healthcare provider in the comfort and privacy of the...
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
May 19, 2020
Lead Product(s) : Ospemifene
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Plushcare
Deal Size : Undisclosed
Deal Type : Partnership
Reset All
